StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96−0.10 (-1.24%)

Close on Nov 17, 2026Market cap $1.31BP/E –Yield –

Earnings

Novavax's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$68.00M
-2.9% on a year earlier
EPS, Q3 FY2026
-$0.19
-$1.25 a year earlier
Latest guidance
Raised
Nov 5, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Novavax's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$68.00M-2.9%-$0.19Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open$57.00M-76.2%-$0.32Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open$140.00M-79.0%-$0.06Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$147.00M+67.0%$0.11Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$70.00M-17.6%-$1.25Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025before the open$239.00M-42.4%$0.62Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open$667.00M+609.6%$2.93Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open$88.00M-69.8%-$0.51Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open$85.00M-54.5%-$0.76Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$415.00M-2.1%$0.99Release
Q1 FY2024ended Mar 31, 2024May 10, 2024before the open$94.00M+16.0%-$1.05Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Novavax's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Adjusted Total Revenuenon-GAAPFY2026$385.00M – $415.00M$230.00M – $270.00MRaisedNov 5, 2026
Adjusted Total Revenuenon-GAAPFY2026$235.00M – $275.00M$230.00M – $270.00MRaisedAug 6, 2026
Nuvaxovid Product SalesFY2026$35.00M – $45.00M$40.00M – $50.00MLoweredAug 6, 2026
combined R&D and SG&A expensesFY2026$350.00M–NewNov 12, 2024
Combined R&D and SG&A ExpensesGAAPFY2026$375.00M – $395.00M$380.00M – $420.00MLoweredNov 5, 2026
Combined R&D and SG&A ExpensesGAAPFY2026$370.00M – $410.00M–NewAug 6, 2026
Combined R&D and SG&A ExpensesFY2026$380.00M – $420.00M–NewMay 6, 2026
Less: R&D ReimbursementsFY2026-$80.00M – -$70.00M–LoweredMay 6, 2026
Non-GAAP combined R&D and Selling, General and Administrative (SG&A) expensesnon-GAAPFY2026$325.00M–NewMay 6, 2026
Non-GAAP Combined R&D and SG&A Expensesnon-GAAPFY2026$315.00M – $335.00M$310.00M – $340.00MNarrowedNov 5, 2026
Non-GAAP Combined R&D and SG&A Expensesnon-GAAPFY2026$310.00M – $340.00M$310.00M – $340.00MReaffirmedAug 6, 2026
Combined R&D and SG&A Expenses, Net of Partner Reimbursementnon-GAAPFY2027$250.00M–NewJan 12, 2026
Non-GAAP combined R&D and Selling, General and Administrative (SG&A) expensesnon-GAAPFY2027$225.00M–LoweredMay 6, 2026
Non-GAAP combined R&D and SG&A expensesnon-GAAPFY2028$150.00M – $200.00M–NewMay 6, 2026

Guidance vs results

The last range Novavax gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$35.00M – $45.00M$1.12BΣ4QAbove range
Q1 FY2024Revenue$100.00M$94.00MBelow range

Guidance history

Every forecast Novavax put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Non-GAAP Combined R&D and SG&A ExpensesFY2026$315.00M – $335.00MNarrowed
Nov 5, 2026Combined R&D and SG&A ExpensesFY2026$375.00M – $395.00MLowered
Nov 5, 2026Adjusted Total RevenueFY2026$385.00M – $415.00MRaised
Aug 6, 2026Combined R&D and SG&A ExpensesFY2026$370.00M – $410.00MNew
Aug 6, 2026Non-GAAP Combined R&D and SG&A ExpensesFY2026$310.00M – $340.00MReaffirmed
Aug 6, 2026Adjusted Total RevenueFY2026$235.00M – $275.00MRaised
Aug 6, 2026Nuvaxovid Product SalesFY2026$35.00M – $45.00MLowered
Aug 6, 2026Adjusted Licensing, Royalties and Other RevenueFY2026$155.00M – $175.00MRaised
Aug 6, 2026Adjusted Supply SalesFY2026$45.00M – $55.00MLowered
May 6, 2026Non-GAAP combined R&D and Selling, General and Administrative (SG&A) expensesFY2026$325.00MNew
May 6, 2026Non-GAAP combined R&D and SG&A expensesFY2028$150.00M – $200.00MNew
May 6, 2026Non-GAAP combined R&D and Selling, General and Administrative (SG&A) expensesFY2027$225.00MLowered
May 6, 2026Combined R&D and SG&A ExpensesFY2026$380.00M – $420.00MNew
May 6, 2026Less: R&D ReimbursementsFY2026-$80.00M – -$70.00MLowered
May 6, 2026Non-GAAP Combined R&D and SG&A ExpensesFY2026$310.00M – $340.00MReaffirmed
May 6, 2026Adjusted Supply SalesFY2026$40.00M – $50.00MRaised
May 6, 2026Nuvaxovid Product Sa lesFY2026$35.00M – $45.00MNew
May 6, 2026Adjusted Total RevenueFY2026$230.00M – $270.00MNew
May 6, 2026Adjusted Licensing, Royalties and Other RevenueFY2026$155.00M – $175.00MRaised
Feb 26, 2026Non-GAAP Combined R&D and SG&A ExpensesFY2026$310.00M – $340.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Novavax filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Update
  9. Update
  10. Update
  11. News
  12. Results
  13. Update
  14. Update
  15. Results

See a number that looks wrong?